Identifying a novel treatment for heart attacks
Professor David Merryman explains how his team targeted the serotonin 2B receptor in animal models to preserve cardiac function six weeks after a heart attack.
List view / Grid view
Articles
SARS-CoV-2 variants: the role of sequencing and vaccine development
Professor Martin Michaelis and Dr Mark Wass explain why new SARS-CoV-2 variants are emerging around the world and how vaccines will have to adapt in response.
A strategy to cloak gene therapy AAV vectors from immune responses
Dr Ying Kai Chan discusses his latest research into how the delivery of AAV vectors for gene therapies can be made safer and more effective.
What we know about COVID-19 and the inflammatory response
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
Developing bioenergetic nanocatalysts, a novel approach to treat neurodegeneration
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
High-throughput laboratory evolution reveals how bacteria gain drug resistance
This article introduces insights into combatting multidrug resistance via high-throughput laboratory evolution, pointing to the mechanisms of underlying evolved drug resistance.
NOX5: a novel target for sensitising melanoma to therapies
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
SARS-CoV-2 and immunology: antibody developments
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Could metabo-oncology be the treatment modality of the future?
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
Could downregulating the Drp1 protein prevent Alzheimer’s progression?
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
Preventing stem cells from transforming into pre-leukaemia stem cells
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
AI advancing drug discovery: the future is multi-cellular studies
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
What is new in the world of imaging?
In this article, Drug Target Review’s Hannah Balfour discusses three of the latest developments in imaging for disease research and drug development.
A novel CAR T-cell therapy to treat lymphomas
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.